Dec 9 Axovant Sciences Ltd
* Says results from both trials are expected in 2017
* Unveils new data analysis showing addition of intepirdine to standard therapy may help people with alzheimer's disease maintain independence longer
* Says has incorporated dependence scale into ongoing intepirdine trials in both alzheimer's disease and dementia with lewy bodies Source text for Eikon: Further company coverage:
PRESS DIGEST- New York Times business news - June 28
June 28 The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.
BRIEF-Canada Goose Holdings prices public secondary offering of 12.5 mln voting shares
* Canada Goose announces pricing of public secondary offering